

**DECLARATION FORM ON NOTHING TO DECLARE OR NOTHING NEW TO
DECLARE FOR USE IN THE INFORMATION EXCHANGE**

Measure	Nothing to declare	Nothing new to declare
A, part I	<input type="checkbox"/>	<input checked="" type="checkbox"/>
A, part 2 (i)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
B (i)	<input type="checkbox"/>	<input type="checkbox"/>
B (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
C	<input checked="" type="checkbox"/>	<input type="checkbox"/>
D	<input checked="" type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input checked="" type="checkbox"/>
F	<input checked="" type="checkbox"/>	<input type="checkbox"/>
G	<input type="checkbox"/>	<input checked="" type="checkbox"/>

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: 2007-04-15

State Party to the Convention: Republic of Lithuania

CONFIDENCE BUILDING MEASURE A (Part I)

Form A, part 1

Exchange of data on research centres and laboratories¹

1. Name(s) of facility² Microbiological Laboratory of Vilnius Public Health Centre
2. Responsible public or private organization or company Ministry of Health
3. Location and postal address Žolyno str. 36
10210 Vilnius Lithuania
4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence
Ministry of Health
5. Number of maximum containment units³ within the research centre and/or laboratory, with an indication of their respective size (m²)
none
6. If no maximum containment unit, indicate highest level of protection
level 3
7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate
Public health purposes: diagnosis of infectious diseases such as Antrax, Cholera, Brucellosis, Listeriosis, Legionellosis, Botulism and others.
-

1. Name(s) of facility⁴ Lithuanian AIDS Center Laboratory
2. Responsible public or private organization or company Ministry of Health
-

¹The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

²For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

³In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

⁴For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

3. Location and postal address Vytenio str. 59/37
03209 Vilnius
Lithuania
4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence
Ministry of Health
5. Number of maximum containment units⁵ within the research centre and/or laboratory, with an indication of their respective size (m²)
None
6. If no maximum containment unit, indicate highest level of protection
Level 2 (size of containment - 52,39 m²)
7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate
Tested pathogens: HIV, HTLV, enteroviruses and poliomielytis, influenza and parainfluenza, measles, rubella, herpes infections, viral haemorrhagic fevers, parasitoses, tick born diseases, etc.
-

1. Name(s) of facility⁶ National Veterinary laboratory
2. Responsible public or private organization or company National Food and Veterinary Service
3. Location and postal address J.Kairiūkščio 10
08409 Vilnius Lithuania
4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence
National Food and Veterinary Service
5. Number of maximum containment units⁷ within the research centre and/or laboratory, with an indication of their respective size (m²)
none
-

⁵In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

⁶For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

⁷In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

6. If no maximum containment unit, indicate highest level of protection

_____ level 2 _____

7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

_____ Rabies, Leptospyrosis, Anthrax, Tuberculosis, Brucelosis, _____
Salmonellosis and other viral and bacterial diseases of animals

Form A, part 2 (i)

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

Form A, part 2 (ii)

National biological defence research and development programme

NSTR

Form A, part 2 (iii)

National biological defence research and development programme

NSTR

Form B (i)

**Background information on outbreaks of reportable
infectious diseases**

This is in accordance with the WHO International Statistical Classification of Diseases and Related Health Problems, 10th Revision
Certain infectious and parasitic diseases in Lithuania for 2006

WHO Classification of

Disease

Case per year

(1) Human diseases (number of cases per year)

Diseases	2006
AIDS	13
Amebiasis	23
Botulism	3
Brucellosis	0
Campylobacteriosis	624
Chancroid	
Chicken-pox	15941
Chlamydial infections	556
Cholera	0
Diphtheria	0
Giardiasis	17
Gonococcal infections	437
Gonococcal ophthalmia neonatorum	n.a.
H.Influenzae B (invasive)	11
Hepatitis A	99
Hepatitis B	107
Hepatitis C	62
Hepatitis non A-non B	0
Hepatitis other unspecified viral	-
Legionellosis	5
Leprosy	0
Listeriosis	4
Malaria	0
Measles	1
Pneumococcal meningitis	8
Other bacterial meningitis	55
Viral meningitis	308
Meningococcal infections	77
Mumps	74
Paratyphoid	2
Pertussis	6
Plague	0
Poliomyelitis	0
Rabies	0
Rubella	110
Congenital rubella	0
Salmonellosis	3557
Shigellosis	203
Syphilis, Congenital	2
Syphilis, Early Latern	336
Other Syphilis	n.a.
Tetanus	3
Trichinellosis	20
Tuberculosis	1256
Typoid fever	4
Verotoxigenic E.coli infection 0157	0
Yellow Fever	0

Lithuania

Form B (i)

Background information on outbreaks of reportable
infectious diseases

(2) Human diseases (outbreaks)

Diseases	2006 m.
Shigellosis	10
Salmonellosis	79
Trichinellosis	3
Staphylococcal infection (S. aureus)	5
Tick-borne encephalities	0
Rotoviral infection	66
Not confirmed ethiology	35

Form B (ii)

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern

NSTR

4. **CONFIDENCE-BUILDING MEASURE "C":**

- **Encouragement of publication of results and promotion of use of knowledge**

NSTR

Form D

Active promotion of contacts

1. Planned international conferences, symposia, seminars, and other similar forums for exchange

NSTR

2. Information regarding other opportunities

NSTR

Declaration of legislation, regulations and other measures

<u>Relating to</u>	<u>Legislation</u>	<u>Regulations</u>	<u>Other measures</u>	<u>Amended since last year</u>
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES	YES	YES	NO
(b) Exports of micro-organisms* and toxins	YES	YES	YES	NO
(c) Imports of micro-organisms* and toxins	YES	YES	YES	NO

* Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State party.
10 April 1997

2. Past offensive biological research and development programmes:
 - NO

 - Period(s) of activities

 - Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.

3. Past defensive biological research and development programmes:
 - NO

 - Period(s) of activities

 - Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

Form G

Declaration of vaccine production facilities

No vaccines are produced in Lithuania